• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从前列腺到骨骼:前列腺癌骨转移的关键因素。

From prostate to bone: key players in prostate cancer bone metastasis.

机构信息

Section of Urology, Department of Surgery, The University of Chicago, Chicago, IL 60637, USA;

出版信息

Cancers (Basel). 2011;3(1):478-93. doi: 10.3390/cancers3010478.

DOI:10.3390/cancers3010478
PMID:21603150
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3096870/
Abstract

Bone is the most common site for metastasis in human prostate cancer patients. Skeletal metastases are a significant cause of morbidity and mortality and overall greatly affect the quality of life of prostate cancer patients. Despite advances in our understanding of the biology of primary prostate tumors, our knowledge of how and why secondary tumors derived from prostate cancer cells preferentially localize bone remains limited. The physiochemical properties of bone, and signaling molecules including specific chemokines and their receptors, are distinct in nature and function, yet play intricate and significant roles in prostate cancer bone metastasis. Examining the impact of these facets of bone metastasis in vivo remains a significant challenge, as animal models that mimic the natural history and malignant progression clinical prostate cancer are rare. The goals of this article are to discuss (1) characteristics of bone that most likely render it a favorable environment for prostate tumor cell growth, (2) chemokine signaling that is critical in the recruitment and migration of prostate cancer cells to the bone, and (3) current animal models utilized in studying prostate cancer bone metastasis. Further research is necessary to elucidate the mechanisms underlying the extravasation of disseminated prostate cancer cells into the bone and to provide a better understanding of the basis of cancer cell survival within the bone microenvironment. The development of animal models that recapitulate more closely the human clinical scenario of prostate cancer will greatly benefit the generation of better therapies.

摘要

骨骼是人前列腺癌患者中转移最常见的部位。骨骼转移是发病率和死亡率的重要原因,总体上极大地影响了前列腺癌患者的生活质量。尽管我们对原发性前列腺肿瘤的生物学有了更多的了解,但我们对前列腺癌细胞衍生的继发性肿瘤如何以及为何优先定位于骨骼的了解仍然有限。骨骼的物理化学特性,以及包括特定趋化因子及其受体在内的信号分子,在性质和功能上是不同的,但在前列腺癌骨转移中起着错综复杂且重要的作用。在体内研究这些骨转移方面的影响仍然是一个重大挑战,因为能够模拟临床前列腺癌自然史和恶性进展的动物模型非常罕见。本文的目的是讨论:(1)最有可能使骨骼成为有利于前列腺肿瘤细胞生长的环境的特征;(2)在招募和迁移前列腺癌细胞到骨骼中起关键作用的趋化因子信号;(3)目前用于研究前列腺癌骨转移的动物模型。需要进一步的研究来阐明播散的前列腺癌细胞进入骨骼的机制,并更好地理解癌细胞在骨骼微环境中存活的基础。开发更能重现人类前列腺癌临床情况的动物模型将极大地促进更好的治疗方法的产生。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd67/3756373/0bc8c9fb5857/cancers-03-00478f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd67/3756373/b13bc38d0634/cancers-03-00478f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd67/3756373/0bc8c9fb5857/cancers-03-00478f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd67/3756373/b13bc38d0634/cancers-03-00478f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd67/3756373/0bc8c9fb5857/cancers-03-00478f2.jpg

相似文献

1
From prostate to bone: key players in prostate cancer bone metastasis.从前列腺到骨骼:前列腺癌骨转移的关键因素。
Cancers (Basel). 2011;3(1):478-93. doi: 10.3390/cancers3010478.
2
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
3
Osteoid cell-derived chemokines drive bone-metastatic prostate cancer.类骨质细胞衍生的趋化因子驱动骨转移性前列腺癌。
Front Oncol. 2023 Mar 21;13:1100585. doi: 10.3389/fonc.2023.1100585. eCollection 2023.
4
From Tumor to Bone: Growth Factor Receptors as Key Players in Cancer Metastasis.从肿瘤到骨骼:生长因子受体在癌症转移中扮演关键角色
Front Biosci (Landmark Ed). 2024 May 13;29(5):184. doi: 10.31083/j.fbl2905184.
5
Translational models of prostate cancer bone metastasis.前列腺癌骨转移的转化模型。
Nat Rev Urol. 2018 Jul;15(7):403-421. doi: 10.1038/s41585-018-0020-2.
6
Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.前列腺癌进展的分子见解:肿瘤微环境的缺失环节
J Urol. 2005 Jan;173(1):10-20. doi: 10.1097/01.ju.0000141582.15218.10.
7
In vivo models of prostate cancer metastasis to bone.前列腺癌骨转移的体内模型。
J Urol. 2005 Sep;174(3):820-6. doi: 10.1097/01.ju.0000169133.82167.aa.
8
Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis.骨髓微环境作为前列腺癌骨转移的调控因子和治疗靶点。
Calcif Tissue Int. 2018 Feb;102(2):152-162. doi: 10.1007/s00223-017-0350-8. Epub 2017 Nov 1.
9
Prostate cancer cells preferentially home to osteoblast-rich areas in the early stages of bone metastasis: evidence from in vivo models.前列腺癌细胞在骨转移的早期阶段优先归巢到成骨细胞丰富的区域:来自体内模型的证据。
J Bone Miner Res. 2014 Dec;29(12):2688-96. doi: 10.1002/jbmr.2300.
10
Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.骨骼转移及抗雄激素药物和骨靶向药物对去势抵抗性前列腺癌患者的影响。
Cancer Treat Rev. 2016 Mar;44:61-73. doi: 10.1016/j.ctrv.2016.02.002. Epub 2016 Feb 12.

引用本文的文献

1
Low-magnitude high-frequency vibration reduces prostate cancer growth and extravasation .低强度高频振动可抑制前列腺癌生长及扩散。
Mechanobiol Med. 2024 Aug 26;2(4):100095. doi: 10.1016/j.mbm.2024.100095. eCollection 2024 Dec.
2
Traditional Prostate Cancer Risk Assessment Scales Do Not Predict Outcomes from Brain Metastases: A Population-Based Predictive Nomogram.传统前列腺癌风险评估量表无法预测脑转移的预后:一项基于人群的预测列线图。
Cancers (Basel). 2024 Aug 30;16(17):3029. doi: 10.3390/cancers16173029.
3
The Pros and Cons of Estrogens in Prostate Cancer: An Update with a Focus on Phytoestrogens.

本文引用的文献

1
Loss of PTEN permits CXCR4-mediated tumorigenesis through ERK1/2 in prostate cancer cells.PTEN 的缺失通过 ERK1/2 允许 CXCR4 介导的前列腺癌细胞肿瘤发生。
Mol Cancer Res. 2011 Jan;9(1):90-102. doi: 10.1158/1541-7786.MCR-10-0235. Epub 2010 Nov 12.
2
The crossover of bisphosphonates to cancer therapy.双膦酸盐类药物向癌症治疗的交叉。
Ann N Y Acad Sci. 2010 Nov;1211:107-12. doi: 10.1111/j.1749-6632.2010.05812.x.
3
CXCR7 protein is not expressed on human or mouse leukocytes.CXCR7 蛋白在人或鼠的白细胞上不表达。
雌激素在前列腺癌中的利弊:聚焦植物雌激素的最新进展
Biomedicines. 2024 Jul 23;12(8):1636. doi: 10.3390/biomedicines12081636.
4
3D Hydrogel Coculture System Provides Mechanistic Insights into Prostate Cancer Bone Metastasis.3D 水凝胶共培养系统为前列腺癌骨转移提供机制见解。
ACS Appl Mater Interfaces. 2024 May 22;16(20):25773-25787. doi: 10.1021/acsami.4c03453. Epub 2024 May 13.
5
Microfluidics-Based Technologies for the Assessment of Castration-Resistant Prostate Cancer.基于微流控技术的去势抵抗性前列腺癌评估方法
Cells. 2024 Mar 26;13(7):575. doi: 10.3390/cells13070575.
6
Engineering models of head and neck and oral cancers on-a-chip.头颈部及口腔癌的芯片工程模型。
Biomicrofluidics. 2024 Mar 6;18(2):021502. doi: 10.1063/5.0186722. eCollection 2024 Mar.
7
Osteoclasts directly influence castration-resistant prostate cancer cells.破骨细胞直接影响去势抵抗性前列腺癌细胞。
Clin Exp Metastasis. 2022 Oct;39(5):801-814. doi: 10.1007/s10585-022-10179-2. Epub 2022 Aug 16.
8
What are the efficacy and safety of bisphosphonates and RANK-ligand-inhibitors for men with prostate cancer and bone metastases? - A Cochrane Review summary with commentary.双膦酸盐和RANK配体抑制剂对前列腺癌骨转移男性患者的疗效和安全性如何?——Cochrane系统评价总结及述评
J Musculoskelet Neuronal Interact. 2021 Dec 1;21(4):451-454.
9
Tumor Microenvironment in Prostate Cancer: Toward Identification of Novel Molecular Biomarkers for Diagnosis, Prognosis, and Therapy Development.前列腺癌中的肿瘤微环境:迈向用于诊断、预后和治疗开发的新型分子生物标志物的鉴定
Front Genet. 2021 Mar 26;12:652747. doi: 10.3389/fgene.2021.652747. eCollection 2021.
10
Medullary Aplasia Revealing a Metastatic Prostatic Adenocarcinoma.髓质发育不全揭示转移性前列腺腺癌
Case Rep Urol. 2021 Feb 23;2021:8898130. doi: 10.1155/2021/8898130. eCollection 2021.
J Immunol. 2010 Nov 1;185(9):5130-9. doi: 10.4049/jimmunol.1001660. Epub 2010 Oct 1.
4
Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial.在无疼痛或仅有轻度疼痛症状的转移性去势抵抗性前列腺癌和骨转移患者中,特异性内皮素 A 受体拮抗剂 Zibotentan(ZD4054)的最终安全性和疗效分析:一项双盲、安慰剂对照、随机的 II 期试验。
BJU Int. 2010 Oct;106(7):966-73. doi: 10.1111/j.1464-410X.2010.09638.x.
5
How do bisphosphonates inhibit bone metastasis in vivo?双膦酸盐如何在体内抑制骨转移?
Neoplasia. 2010 Jul;12(7):571-8. doi: 10.1593/neo.10282.
6
Cancer statistics, 2010.癌症统计数据,2010 年。
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. doi: 10.3322/caac.20073. Epub 2010 Jul 7.
7
Overlapping and distinct role of CXCR7-SDF-1/ITAC and CXCR4-SDF-1 axes in regulating metastatic behavior of human rhabdomyosarcomas.CXCR7-SDF-1/ITAC 和 CXCR4-SDF-1 轴在调节人横纹肌肉瘤转移行为中的重叠和独特作用。
Int J Cancer. 2010 Dec 1;127(11):2554-68. doi: 10.1002/ijc.25245.
8
CXCR7 functions as a scavenger for CXCL12 and CXCL11.CXCR7 作为 CXCL12 和 CXCL11 的清除剂发挥作用。
PLoS One. 2010 Feb 11;5(2):e9175. doi: 10.1371/journal.pone.0009175.
9
CXCL12-induced chemotaxis is impaired in T cells from patients with ZAP-70-negative chronic lymphocytic leukemia.CXCL12 诱导的趋化作用在 ZAP-70 阴性慢性淋巴细胞白血病患者的 T 细胞中受损。
Haematologica. 2010 May;95(5):768-75. doi: 10.3324/haematol.2009.013995. Epub 2010 Feb 9.
10
Beta-arrestin- but not G protein-mediated signaling by the "decoy" receptor CXCR7.β-arrestin 而非 G 蛋白介导的“诱饵”受体 CXCR7 的信号转导。
Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):628-32. doi: 10.1073/pnas.0912852107. Epub 2009 Dec 17.